4/24
10:12 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
4/24
10:12 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
4/24
08:10 am
NBIX
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
4/24
08:10 am
NBIX
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $200.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $200.00 price target on the stock.
4/24
07:24 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
4/24
07:24 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
4/24
07:04 am
NBIX
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $170.00 price target on the stock, up previously from $140.00.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $170.00 price target on the stock, up previously from $140.00.
4/23
08:40 am
NBIX
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/23
08:36 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
4/23
08:36 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
4/17
01:17 pm
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
4/17
01:17 pm
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
4/10
10:19 am
NBIX
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
4/10
09:44 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
3/20
08:03 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
3/13
08:37 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
3/13
08:37 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
2/23
12:40 pm
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
2/8
11:24 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
2/8
11:24 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
2/8
10:28 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
2/8
10:28 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
2/8
08:41 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
2/8
08:41 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX
1/25
09:15 am
NBIX
Rating for NBIX
Low
Report
Rating for NBIX